Evidence map›Paper›PMID 25929202›Full record

ArticleSleep & breathing = Schlaf & Atmung2016

Effects of mandibular advancement device treatment on arterial stiffness and glucose metabolism in patients with mild to moderate obstructive sleep apnea: a prospective 1 year study.

Tea Galic, Josko Bozic, Natalija Ivkovic, Grgo Gunjaca, Tina Kurir Ticinovic, Zoran Dogas

Abstract readClinical Study
PubMed Publisher
In one paragraph

Article in Sleep & breathing = Schlaf & Atmung, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. The role of oral appliance therapy in obstructive sleep apnoea.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  10. The face of Dental Sleep Medicine in the 21st century.Journal of oral rehabilitation · 2020
    Review
  11. Article
  12. Update on Oral Appliance Therapy for OSA.Current sleep medicine reports · 2017
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Tea GalicStudy of Dental Medicine, University of Split School of Medicine, Soltanska 2, Split, Croatia.
Josko BozicDepartment of Pathophysiology, University of Split School of Medicine, Soltanska 2, Split, Croatia.
Natalija IvkovicSplit Sleep Medicine Center, University of Split School of Medicine, Soltanska 2, Split, Croatia.
Grgo GunjacaDepartment of Pharmacology, University of Split School of Medicine, Soltanska 2, Split, Croatia.
Tina Kurir TicinovicDepartment of Pathophysiology, University of Split School of Medicine, Soltanska 2, Split, Croatia.
Zoran DogasSplit Sleep Medicine Center, University of Split School of Medicine, Soltanska 2, Split, Croatia. zdogas@mefst.hr.
University of Split · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

STUDY

objectivesAn independent association between obstructive sleep apnea (OSA) and cardiovascular events has been reported, suggesting that OSA may lead to cardiometabolic dysregulation. We prospectively investigated the effect of mandibular advancement device (MAD) treatment on arterial stiffness, glucose metabolism, and certain inflammatory markers as predictors of cardiometabolic risk in mild to moderate OSA patients.

methodsA total of 18 patients with mild to moderate OSA were prospectively enrolled in the study to determine the effects of MAD treatment at 3 months and 1 year following initiation of the treatment. Sleep studies, arterial stiffness assessment, and laboratory analyses were obtained at the baseline and at the time of follow-up. The data collected at 1 year were compared to baseline values.

resultsThere was a significant decrease in apnea-hypopnea index (AHI) after 1 year of treatment when compared to baseline (22.9 ± 5.9 to 9.7 ± 4.5, P < 0.001). Furthermore, MAD treatment was associated with reduced levels of fasting plasma glucose values after 1 year of treatment (5.3 ± 0.5 to 4.9 ± 0.5 mmol/L, P < 0.001), as well as fasting plasma insulin values (14.1 ± 7.8 to 10.9 ± 6.4 μU/mL, P < 0.05) and HOMA-IR (3.3 ± 1.8 to 2.4 ± 1.4, P < 0.001). There was significant improvement in pulse wave velocity (9.3 ± 1.9 m/s at baseline to 8.1 ± 1.7 m/s, P < 0.05) after 1 year of treatment. Plasma level of an inflammatory marker fibrinogen decreased significantly from 3.4 ± 0.7 at baseline to 3.0 ± 0.9, (P < 0.05) at 1-year follow-up.

conclusionsThe MAD treatment improved arterial stiffness, glucose metabolism, and insulin resistance in mild to moderate OSA patients after 1 year of treatment.

Indexed as

AdultBlood GlucoseFemaleFibrinogenFollow-Up StudiesHumansInflammation MediatorsInsulin ResistanceMaleMandibular AdvancementPolysomnographyProspective StudiesPulse Wave AnalysisSleep Apnea, ObstructiveVascular StiffnessBlood GlucoseFibrinogenInflammation MediatorsArterial stiffnessCardiovascular riskGlucose metabolismMandibular advancement deviceObstructive sleep apnea

Identifiers

PMID25929202
OpenAlexW2003022382

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.